Blockchain Registration Transaction Record
Elicio Therapeutics Unveils Promising Phase 1a Data for ELI-002 7P in mKRAS Tumors
Elicio Therapeutics announces promising phase 1a data for ELI-002 7P in mKRAS tumors, offering hope to patients with aggressive cancers. The innovative approach and encouraging early results signify a significant advancement in cancer treatment.
The preliminary data from Elicio Therapeutics' AMPLIFY-7P Phase 1a Study suggests a potential breakthrough in treating difficult-to-target KRAS mutated cancers, offering hope to patients with aggressive forms of the disease. The innovative approach of using lymph node-targeted immunotherapies and the encouraging early results from the ongoing trials signify a significant advancement in cancer treatment, with the potential to broaden the patient population for the ELI-002 treatment.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x76015bad49dc74378a2f09c4dacd961206332db2afc733c0f0fd35a874f8ace8 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | pendT1Fl-9677882c024ae69dc2dc3456d750d5a3 |